Medical and developmental outcomes of bevacizumab versus laser for retinopathy of prematurity

Infants with stage 3+ retinopathy of prematurity (ROP) in zone I or zone II posterior were randomized to initial treatment with bevacizumab or laser in a multicenter trial (BEAT-ROP). The purpose of this study was to assess the effects of bevacizumab on nonophthalmologic outcomes. At one study site,...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of AAPOS 2018-02, Vol.22 (1), p.61-65.e1
Hauptverfasser:	Kennedy, Kathleen A., Mintz-Hittner, Helen A.
Format:	Artikel
Sprache:	eng
Schlagworte:	Angiogenesis Inhibitors - therapeutic use Bevacizumab - therapeutic use Female Gestational Age Humans Infant Infant, Newborn Infant, Premature Intravitreal Injections Laser Coagulation Length of Stay Male Retinopathy of Prematurity - therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Infants with stage 3+ retinopathy of prematurity (ROP) in zone I or zone II posterior were randomized to initial treatment with bevacizumab or laser in a multicenter trial (BEAT-ROP). The purpose of this study was to assess the effects of bevacizumab on nonophthalmologic outcomes. At one study site, inborn infants of
ISSN:	1091-8531 1528-3933 1528-3933
DOI:	10.1016/j.jaapos.2017.10.006